ProSensa Holding N.V. (RNA) And Partners Awarded Second European Consortium FP7 Research Grant
11/25/2013 9:15:07 AM
Leiden, The Netherlands and Newcastle, UK, Nov. 25, 2013 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, and Newcastle University, UK, have announced the award of a second Framework Programme 7 (FP7) research grant from the European Commission. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD).
Help employers find you! Check out all the jobs and post your resume.
comments powered by